Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CE211NS21 in Severe AQP4-IgG-Positive NMOSD Relapse
NCT07595965Phase 1Not yet recruiting
- Sponsor
- Corestemchemon
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of CE211NS21 in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Corestemchemon. Primary endpoints: Dose-Limiting Toxicity up to 4 weeks and Adverse Events up to 4 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
CE211NS21
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT07595965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07595965.